Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries ADR (NY: TEVA )

16.50 -0.31 (-1.84%)
Official Closing Price Updated: 7:00 PM EST, Dec 13, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Teva Pharmaceutical Industries ADR

< Previous 1 2 3 4 5 6 7 8 Next >
Teva Announces Intention to Divest API Business as Part of Pivot to Growth Strategy
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results and 2024 Financial Guidance at 8 a.m. ET on January 31, 2024
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva and Biolojic Design Announce Exclusive License Agreement for the Development of a Therapeutic Antibody for Atopic Dermatitis and Asthma
From Teva Pharmaceutical Industries Limited
Via Business Wire
New Post Hoc Phase 3 Data Analysis Shows AJOVY® (fremanezumab) Reduced Migraine Attacks in Adults with Migraine and Co-morbid Obesity
From Teva Pharmaceutical Industries Limited
Via Business Wire
MarketBeat Week in Review – 11/27 - 12/1
Stocks closed the week at or near yearly highs after subdued inflation numbers suggest the Federal Reserve will continue to pause on raising rates 
Via MarketBeat
Topics Economy Stocks
Exposures Economy Interest Rates US Equities
Teva Completes Closing of Exclusive Collaboration Deal to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Pharma is the way to play the re-rise of generic drugs
Generic and specialty pharmaceutical company, Teva Pharmaceutical's stock, has underperformed for years, but a potential spinoff may be a catalyst for growth 
Via MarketBeat
Teva to Present at the 6th Annual Evercore ISI HealthCONx Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
2 overlooked stocks that crushed earnings but traded lower
As the third quarter 2023 earnings season ends, it's worth looking back to see which stocks may have been overlooked or mispriced on their results 
Via MarketBeat
Exposures Product Safety
Teva Announces Approval of a Generic Version of Forteo® (teriparatide injection), in the U.S.
From Teva Pharmaceutical Industries Limited
Via Business Wire
Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
From Royalty Pharma plc
Via GlobeNewswire
Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports Third Quarter 2023 Financial Results and Increases Revenue Guidance
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva appoints new CEO for Teva api, its Active Pharmaceutical Ingredients Business
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present New Data Supporting Safety, Efficacy and Real-World Effectiveness of AUSTEDO® (deutetrabenazine) Tablets at the 2023 HSG Annual Meeting
From Teva Pharmaceutical Industries Limited
Via Business Wire
UZEDY™ (risperidone) Extended-Release Injectable Suspension Significantly Prolongs Time to Schizophrenia Relapse in RISE Study Results Published in The Lancet Psychiatry
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Provide Second Round of Funding to Clinics in California, Florida and New Jersey as Part of $2 Million Commitment Through Community Routes: Access to Mental Health Care Program
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Phase IV UNITE Study Shows AJOVY® (fremanezumab) Reduced Migraine Attacks and Depression Symptoms in Migraine Sufferers with Major Depressive Disorder
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Host Conference Call to Discuss Third Quarter 2023 Financial Results at 8 a.m. ET on November 8, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Sanofi and Teva Announce Exclusive Collaboration to Deliver Inflammatory Bowel Disease Treatment
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Changes to Executive Management Team
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present at the 21st Annual Morgan Stanley Global Healthcare Conference
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva to Present Data for AUSTEDO® XR (deutetrabenazine) Extended-Release Tablets, AUSTEDO® (deutetrabenazine) Tablets and UZEDY™ (risperidone) Extended-Release Injectable Suspension at Psych Congress 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Settles Price Fixing Charges With U.S. DOJ
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Reports Second Quarter 2023 Financial Results
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Announces Appointment of Dr. Angus Grant to Executive Vice President, Business Development
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Teva Pharmaceutical Industries Limited
Via Business Wire
Teva Pharmaceuticals and Alvotech Provide Update on Strategic Biosimilars Partnership
From Alvotech
Via GlobeNewswire
Teva to Host Conference Call to Discuss Second Quarter 2023 Financial Results at 8 a.m. ET on August 2, 2023
From Teva Pharmaceutical Industries Limited
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.